洞不全症候群患者における、発作性心房細動に対するロサルタンの予防効果-ペースメーカー心内電位の記録から- by 瀧井 英一
1 
 
Beneficial Effects of Losartan for Prevention of Paroxysmal Atrial 
Fibrillation in Patients with Sick Sinus Syndrome 
-Analysis with Memory Function of Pacemaker- 
 
Eiichi Takii, MD, Tomohito Inage, MD, Teruhisa Yoshida, MD, 
Masatsugu Ohe, MD, Takeki Gondo, MD, Go Haraguchi, MD, 
Shogo Ito, MD, Jun Kmanomido, MD and Tsutomu Imaizumi,  
MD and Yoshihiro Fukuomoto, MD 
 
Department of Internal Medicine, Division of Cardio-Vascular Medicine, 
Kurume University School of Medicine, Kurume, Japan 
Address for Correspondence: Tomohito Inage 
Department of Internal Medicine, Division of Cardio-Vascular  
Medicine, Kurume University School of Medicine, 67  
Asahi-machi, Kurume 830-0011, Japan 
Phone:＋81-942-31-7562 
Fax:＋81-942-33-6509 
E-mail:inage@med.kurume-u.ac.jp 
2 
 
Abstract 
Aims Renin-angiotensin system (RAS) inhibitors may be useful in 
preventing the occurrence of paroxysmal atrial fibrillation (PAF). However, 
evaluation of such effect is difficult because many PAF episodes are 
asymptomatic and not all episodes are detected by intermittent 
electrocardiographic monitoring. A pacemaker has been developed with 
dedicated functions for AF detection and electrocardiogram storage. 
Accordingly, we examined the effect of losartan, an angiotensin receptor 
blocker on PAF occurrence using this new modality. 
Methods and Results We enrolled 70 consecutive patients who had 
undergone dual-chamber pacemaker implantation for sick sinus syndrome. 
Finally, 62 patients participated in the study. Thirty patients were 
randomized to the losartan group (mean 43±12 mg/day) and 32 patients to 
the control group. They were followed-up for 3 months. The frequency, the 
maximum duration and the total duration of PAF recorded by the stored 
electrocardiograms during the 3-month follow-up period were compared 
between the two groups. The change in the frequency of PAF from the 
observation period in the losartan and control groups was similar (-35±25 
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times vs. -67±62 times; NS). However, the change in the maximum 
duration and the total duration of PAF was significantly shorter in the 
losartan group than in the control group (-493±158 min vs. -10±69 min; 
p<0.05,  -4007±2334 min vs. 1119±714 min; p<0.05, respectively).  
Conclusion Losartan suppressed the maximum duration and the total 
duration of PAF in patients with sick sinus syndrome without 
hemodynamic changes. This is the first study to show the effect of a 
renin-angiotensin system inhibitor on the secondary prevention of PAF 
using the dedicated functions of a pacemaker for PAF detection and 
electrocardiogram storage. 
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Introduction 
Atrial fibrillation (AF) is the most commonly encountered arrhythmia in 
daily clinical practice, with an overall incidence of 0.4%. This incidence 
increases with age 1-2. Although AF is not a fatal arrhythmia, it sometimes 
causes thromboembolic complications, including ischemic stroke. 
Therefore the prevention of AF is important 3-5.  
Recently, several clinical studies have suggested that 
angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor 
blockers (ARBs) may have a beneficial effect on new-onset AF (primary 
prevention)6-9 or recurrent AF (secondary prevention)10-11. However, several 
conflicting results have been reported for secondary prevention, for which 
the following reasons has been considered: previous studies evaluated AF 
only by subjective symptoms, routine electrocardiogram, Holter monitoring, 
or transtelephonic monitoring12-14. It is well-known that a significant 
proportion of paroxysmal atrial fibrillation (PAF) is not always detected by 
intermittent electrocardiogram monitoring and patients may remain 
asymptomatic.  
A pacemaker with dedicated functions for AF detection and 
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electrocardiogram storage has been developed. With pacemaker 
interrogation, we are able to accurately document the frequency and 
duration of every PAF. Accordingly, we examined the effect of losartan, an 
angiotensin receptor blocker, on PAF occurrence in patients who had 
undergone pacemaker implantation for sick sinus syndrome. 
 
Methods 
Patient selection and pacemaker programming 
This study was a prospective and randomized study. The study design is 
illustrated in Figure 1. Consecutive patients who had undergone 
implantation of a dual chamber pacemaker for sick sinus syndrome  
between December 2008 and December 2011 were screened. Patients were 
excluded from the study if they had persistent or permanent AF, a left 
atrium size > 50mm by transthoracic echocardiography, New York Heart 
Association heart failure class Ⅲ or Ⅳ, a pacemaker implanted less than 
one month prior to entry into the study, or valvular heart diseases. They 
were all implanted with a Reply DDDR pacemaker (Sorin, Inc., Clamart, 
France) that posed both dedicated functions for PAF detection even at a 
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high rate and electrocardiogram storage. A right atrial lead was placed at 
the right atrial appendage and a right ventricular lead was placed at the 
mid-septum site in order to obtain normal electrical activation sequence. 
Finally, 70 patients entered the study. PAF was defined with AF burden 
algorithm described previously15. Briefly, for every 32 cycles, the number 
of cycles in the suspected AF phase was counted; if ≧28 cycles fell into a 
window of atrial rate acceleration detection or if ≧18 cycles in the last 2 
groups of 32 cycles were in this phase, then PAF was confirmed. At each 
interrogation, the following data were available and used for the current 
analysis: the frequency of PAF was defined as the total number of atrial 
tachyarrhythmia episodes, and the maximum duration of PAF was defined 
as the longest time of the atrial tachyarrhythmia episodes. Moreover, the 
total duration of PAF was evaluated. A pacing algorithm to suppress PAF 
was not programmed.  
Study procedures 
Before randomization to either the losartan or control group, we observed 
the patients for 3 months, during which time we evaluated the occurrence 
of PAF by the pacemaker functions. Eight patients did not have PAF and 
7 
 
were excluded from the study.  Finally, 62 patients were randomized to the 
losartan group or control group. In the losartan group, losartan was 
prescribed at a mean dose of 43±12 mg/day (25-50 mg/day). Patients were 
followed-up for 3 months. Data on the frequency, the maximum duration 
and the total duration of PAF documented by stored electrocadiograms 
were obtained and compared between the groups. We compared the 
frequency, the maximum duration and the total duration of PAF for last one 
month during observation period and study period because the effect of 
losartan would be most anticipated for the last month. Blood pressure, 
cardiac thoracic ratio (CTR) by chest X-ray, and serum brain natriuretic 
peptide (BNP) levels were evaluated. Septal thickness, posterior wall 
thickness, end-systolic dimension, end-diastolic dimension, ejection 
fraction of the left ventricle, and left atrial dimension were also evaluated 
by echocardiography. Medications other than losartan were not altered 
during the observation and study periods. This study was approved by the 
ethics committee of Kurume University, and all patients provided written 
informed consent to the study.  
Statistical analysis  
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Data were expressed as the mean ± standard error. We analyzed differences 
between the 2 groups using the χ2 test and unpaired student’s t test. The value 
of P < 0.05 was considered significant. 
 
Results 
Baseline Characteristics  
The baseline clinical characteristics of patients in the losartan group vs. 
the control group are shown in Table 1 and were not significantly different. 
Most patients had no structural heart disease and normal left ventricular 
systolic function. The use of ClassⅠantiarrhythmic drugs, β-blockers, 
Ca-blockers, and statins was similar between the two groups, except for 
digitalis. The frequencies of asymptomatic and symptomatic PAF were also 
similar. 
Effects of losartan 
Table 2 shows hemodynamics and cardiac function at the end of the study. 
These parameters were similar between the two groups. The percentages of 
atrial pacing and ventricular pacing were similar between the two groups. 
Figure 2 shows the change in the maximum duration and frequency of 
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PAF from the observation period. The change in the frequency of PAF was 
similar (-34±44 times vs. 6±31 times; NS). However, the change in the 
maximum duration of PAF and the total duration of PAF were significantly 
shorter in the losartan group than in the control group (-493±158 min vs. 
-10±69 min; p<0.05,  -4007±2334 min vs. 1119±714 min; p<0.05, 
respectively). 
 
Discussion 
Although the sample size was small and the study period was short, this is 
the first report to describe the beneficial effects of losartan on PAF 
analyzed by the dedicated functions of a pacemaker. Losartan did not 
suppress the frequency of PAF. However, losartan suppressed the maximum 
duration and the total duration of PAF in patients with sick sinus syndrome. 
Our results may underlie the rationale for the use of angiotensin receptor 
blockers for the secondary prevention of PAF.  
The mechanisms by which losartan exerted its beneficial effects on PAF 
were not elucidated in this study. Several mechanisms have been 
considered. First, alterations in hemodynamics or cardiac function might 
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have contributed. However, this possibility was unlikely because losartan 
did not change blood pressure, ejection fraction, CTR or BNP. The most 
likely reason why losartan did not change hemodynamics or cardiac 
function in our study was that our patients had normal blood pressure and 
normal cardiac function at baseline 16. Second, losartan may have regressed 
remodeling of the heart. In animal models of AF, RAS inhibitors had 
beneficial effects on structural remodeling by reducing atrial fibrosis and 
dilatation17-20. However, this possibility was unlikely because our study 
period was only for 3 months and there were also no changes in the left 
atrial dimension, left ventricular dimension, or wall thickness. We were 
also not able to detect subtle changes in dimensions and fibrosis by 
echocardiography. Another possibility was electrical remodeling; however 
although our results may suggest this possibility, we have no results to 
confirm this other than the shorter maximal duration and total duration 
induced by losartan.    
Many human trial results have been reported, on the secondary prevention 
of PAF by RAS inhibitors, and these results have been conflicting10-14. The 
reasons for this may include the presence or absence of organic heart 
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diseases, presence or absence of cardiac dysfunction, concomitant use of 
anti-arrhythmic drugs or angiotensin converting enzyme inhibitors, and the 
methods used to detect PAF. The above mentioned factors may have 
resulted in the conflicting findings described in previous studies12-14. 
Among them, the most important factor may be the methods used to detect 
PAF. Most previous studies used electrocardiograms to document PAF21. 
Because not all episodes of PAF can be detected by intermittent 
electrocardiography monitoring, the use of pacemaker diagnostics to detect 
all episodes of PAF represents a significant advantage. Although we did not 
compare the detection rate of PAF by intermittent monitoring to that of the 
method used in this study, the detection rate of PAF by intermittent 
monitoring is known to be not so high22. Many episodes of PAF are 
asymptomatic and its symptoms correlate very poorly with real episodes of 
PAF22-24. In our study, the occurrence of asymptomatic PAF was 43% in the 
losartan group and 47% in the control group. Thus, only one half of PAF 
was detected by symptoms in our study. Another issue is cardiac function. 
Several previous studies25 enrolled subjects with depressed cardiac function, 
whereas our study included only subjects with normal cardiac function. 
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Thus, our study is unique in terms of the detection of PAF and selection of 
subjects. 
The clinical significance of our findings may not be so clear because 
losartan only decreased the maximum duration and the total duration of 
PAF and did not reduce the occurrence of PAF. However, managing the 
maximum duration of PAF is important in clinical settings because patients 
with a longer PAF duration are known to be at a higher risk of embolism 
than patients with a shorter PAF duration3. Thus, the effect of losartan on 
PAF duration may be clinically meaningful. However, whether the use of 
losartan in patients with PAF is associated with a lower risk of systemic 
embolization should be investigated. Finally, it is not known whether the 
findings in this study can be caused by other renin-angiotensin system 
inhibitors. Previous studies reported similar findings in different 
populations using different methods 10-11, which suggests that the effect of 
losartan may be a class effect.    
 
Limitations  
The number of subjects may have been too small and the duration of 
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treatment may have been too short to draw any concrete conclusions. The 
findings in this study may only be pertinent to only subjects with sick sinus 
syndrome with normal cardiac function and normal blood pressure. 
We enrolled patients with pacemaker implanted for bradycardia and with 
PAF. Accordingly, all study patients were limited to those with sick sinus 
syndrome. This may be a serious bias. 
 
Conclusion 
Losartan significantly suppressed the maximum duration and the total 
duration of PAF in patients with sick sinus syndrome. These results suggest 
that ARBs may be useful for the secondary prevention of PAF. 
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FIGURE LEGENDS 
 
Figure 1 
Design of the study.  
After enrollment, there was a 3 month observation period. Following this 
patients were randomized to either the losartan group or control group. 
Patients were then followed-up for 3 months. 
 
Figure 2 
The mean ± SE change in the frequency, the maximum duration and the 
total duration of PAF for last one month during observation period in the 
losartan group and control group.  
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The change in the frequency of PAF from baseline was similar in the 
losartan group and control group. However, the maximum duration and 
total duration of PAF was significantly shorter than in the control group in 
the losartan group. 
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Table 1    Baseline clinical characteristics 
Losartan group Control group p value
n=30 n=32   
Age (years)                                                                   75.13±2.19 75.50±1.19 0.87
Male 11 (39%) 14 (43%) 0.57
Cardiovascular disease                                               
 None    16 (54%) 21 (65%) 0.47
 Hypertension 11 (36%) 9 (28%) 0.47
 Coronary artery disease                                           2 (7%) 3 (9%) 0.53
 Cardiomyopathy 1 (3%) 1 (3%) 0.74
Cardiovascular drugs
 ClassⅠantiarrhythmic drugs   9 (32%) 4 (13%) 0.09
 Beta-blockers 8 (29%) 9 (28%) 0.89
 Ca2＋channel blockers                                              10 (35%) 12 (38%) 0.73
 Digitalis 4 (14%) 0 (0%) 0.05
 Statin 5 (18%) 6 (19%) 0.83
Subjective symptom of PAF                                        
 symptomatic PAF 17 (57%) 17 (53%) 0.78
 asymptomatic PAF 13 (43%) 15 (47%) 0.78
Systolic blood pressure (mmHg)                               128.40±2.18 122.50±2.38 0.07
Diastolic blood pressure (mmHg) 68.00±1.85 63.00±1.74 0.05
CTR (%) 50.42±0.95 50.16±0.86 0.89
BNP (pg/ml) 126.61±23.04 120.20±24.65 0.85
Echocardiographic parameters
 Septal wall thickness (mm) 9.93±0.23 9.84±0.17 0.76
 Posterior wall thickness (mm) 10.10±0.18 9.69±0.18 0.74
 Left atrial inferosuperior dimention (mm) 38.97±0.86 39.34±0.59 0.72
 Endo-systolic left ventricular dimension (mm) 29.53±0.43 29.78±0.67 0.76
 Endo-diastolic left ventricular dimension (mm) 45.87±0.53 45.88±0.36 0.78
 Ejection fraction (%)   66.93±1.04 65.94±0.93 0.47
Pacing rate 
Atrial pacing (%) 41.53±5.84 45.78±4.31 0.56
Ventricular pacing (%) 45.93±8.19 48.75±7.06 0.79
PAF
Frequency (n) 223.73±128.39 298.06±72.58 0.61
Maximum duration (min) 1319.76±318.38 1011.78±236.25 0.44
Total duration (min) 17553.81±5566.06 13721.44±4003.32 0.29
CTR:Cardiothoracic ratio, BNP:Brain natriuretic peptide.
Table 2    Clinical characteristics at the end of the study 
Losartan group Control group p value
n=30 n=32   
Systolic blood pressure (mmHg)                               128.90±1.99 124.38±2.37 0.16 
Diastolic blood pressure (mmHg) 66.13±1.71 64.56±1.59 0.51 
CTR (%) 50.57±0.96 50.73±0.86 0.84 
BNP (pg/ml) 136.63±28.85 128.05±29.37 0.84 
Echocardiographic parameters
 Septal wall thickness (mm) 10.00±0.19 9.47±0.16 0.76 
 Posterior wall thickness (mm) 10.03±0.19 9.72±0.17 0.74 
 Left atrial inferosuperior dimention (mm) 39.27±0.84 40.75±0.56 0.15 
 Endo-systolic left ventricular dimension (mm) 29.07±0.41 29.54±0.68 0.76 
 Endo-diastolic left ventricular dimension (mm) 45.73±0.49 45.47±0.47 0.78 
 Ejection fraction (%)   67.20±0.73 66.13±1.00 0.28 
Pacing rate 
Atrial pacing (%) 41.07±6.04 41.41±5.08 0.97 
Ventricular pacing (%) 48.37±7.91 50.59±6.62 0.83 
PAF
Frequency (n) 189.83±89.46 303.97±61.88 0.30 
Maximum duration (min) 737.71±222.79 1030.63±264.63 0.42 
Total duration (min) 1171.10±3892.18 13064.44±3471.28 0.35 
CTR:Cardiothoracic ratio, BNP:Brain natriuretic peptide.
